Stay updated with breaking news from Adapted Mayo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission and key secondary endpoints as an induction and maintenance...
Rinvoq (upadacitinib), an anti-inflammatory, was found to be safe and effective in treating moderate-to-severe ulcerative colitis in adults.
Post-hoc analysis showed symptom relief as early as day 1 with the JAK inhibitor
RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who...
Press release content from PR Newswire. The AP news staff was not involved in its creation.